Sarepta Therapeutics, Inc.

NasdaqGS:SRPT Stock Report

Market Cap: US$11.6b

Sarepta Therapeutics Valuation

Is SRPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SRPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SRPT ($121.9) is trading below our estimate of fair value ($375.45)

Significantly Below Fair Value: SRPT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SRPT?

Key metric: As SRPT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SRPT. This is calculated by dividing SRPT's market cap by their current earnings.
What is SRPT's PE Ratio?
PE Ratio95.6x
EarningsUS$121.85m
Market CapUS$11.64b

Price to Earnings Ratio vs Peers

How does SRPT's PE Ratio compare to its peers?

The above table shows the PE ratio for SRPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.5x
NBIX Neurocrine Biosciences
35.8x30.8%US$13.8b
BMRN BioMarin Pharmaceutical
39.4x27.9%US$12.7b
ROIV Roivant Sciences
1.9x-58.7%US$8.7b
EXEL Exelixis
20.7x17.2%US$9.7b
SRPT Sarepta Therapeutics
95.6x43.0%US$11.6b

Price-To-Earnings vs Peers: SRPT is expensive based on its Price-To-Earnings Ratio (95.6x) compared to the peer average (24.5x).

Price to Earnings Ratio vs Industry

How does SRPT's PE Ratio compare vs other companies in the US Biotechs Industry?

11 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ROIV Roivant Sciences
1.9x-58.7%US$8.74b
AGIO Agios Pharmaceuticals
2.9x-57.3%US$1.95b
INBX Inhibrx Biosciences
0.1xn/aUS$209.76m
DTIL Precision BioSciences
3x-41.0%US$34.52m
SRPT 95.6xIndustry Avg. 15.4xNo. of Companies11PE020406080100+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SRPT is expensive based on its Price-To-Earnings Ratio (95.6x) compared to the US Biotechs industry average (15.4x).

Price to Earnings Ratio vs Fair Ratio

What is SRPT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SRPT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio95.6x
Fair PE Ratio42.6x

Price-To-Earnings vs Fair Ratio: SRPT is expensive based on its Price-To-Earnings Ratio (95.6x) compared to the estimated Fair Price-To-Earnings Ratio (42.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SRPT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$121.90
US$185.10
+51.8%
17.4%US$219.00US$75.00n/a21
Dec ’25US$133.34
US$183.82
+37.9%
17.1%US$219.00US$80.00n/a22
Nov ’25US$123.29
US$189.91
+54.0%
12.3%US$220.00US$147.12n/a21
Oct ’25US$122.33
US$194.36
+58.9%
10.2%US$220.00US$148.00n/a19
Sep ’25US$135.78
US$193.59
+42.6%
10.2%US$220.00US$148.00n/a20
Aug ’25US$144.01
US$198.28
+37.7%
11.3%US$235.00US$148.00n/a21
Jul ’25US$156.75
US$197.81
+26.2%
13.0%US$235.00US$131.86n/a22
Jun ’25US$129.86
US$166.99
+28.6%
13.4%US$224.00US$128.00n/a22
May ’25US$130.90
US$164.69
+25.8%
14.3%US$224.00US$128.00n/a20
Apr ’25US$128.40
US$164.33
+28.0%
14.1%US$224.00US$128.00n/a21
Mar ’25US$128.67
US$164.42
+27.8%
14.2%US$224.00US$128.00n/a21
Feb ’25US$122.83
US$147.56
+20.1%
20.5%US$224.00US$103.00n/a21
Jan ’25US$96.43
US$135.84
+40.9%
26.4%US$224.00US$80.00n/a20
Dec ’24US$84.44
US$139.22
+64.9%
27.7%US$224.00US$80.00US$133.3418
Nov ’24US$76.52
US$138.24
+80.7%
30.4%US$220.00US$40.00US$123.2917
Oct ’24US$121.22
US$181.72
+49.9%
12.6%US$223.00US$139.00US$122.3318
Sep ’24US$122.51
US$179.47
+46.5%
13.5%US$223.00US$139.00US$135.7819
Aug ’24US$107.53
US$179.78
+67.2%
13.4%US$221.00US$139.00US$144.0118
Jul ’24US$114.52
US$178.63
+56.0%
13.1%US$218.00US$139.00US$156.7519
Jun ’24US$124.28
US$177.70
+43.0%
12.2%US$218.00US$139.00US$129.8620
May ’24US$125.11
US$171.28
+36.9%
11.4%US$206.00US$139.00US$130.9018
Apr ’24US$137.83
US$170.44
+23.7%
11.6%US$206.00US$139.00US$128.4018
Mar ’24US$145.63
US$168.84
+15.9%
14.5%US$226.00US$125.00US$128.6719
Feb ’24US$122.36
US$149.44
+22.1%
14.2%US$195.00US$108.00US$122.8318
Jan ’24US$129.58
US$145.95
+12.6%
14.8%US$190.00US$101.00US$96.4320
Dec ’23US$122.98
US$140.10
+13.9%
16.1%US$190.00US$100.00US$84.4420

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 05:12
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sarepta Therapeutics, Inc. is covered by 53 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Huidong WangBarclays
Zhiqiang ShuBerenberg